Zevra Therapeutics (NASDAQ:ZVRA) Given New $25.00 Price Target at Maxim Group

Zevra Therapeutics (NASDAQ:ZVRA) had its target price boosted by Maxim Group from $18.00 to $25.00 in a note issued to investors on Tuesday, Briefing.com reports. The firm presently has a “buy” rating on the stock. Maxim Group’s target price would indicate a potential upside of 229.82% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity Group dropped their price objective on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, September 18th. HC Wainwright lifted their price objective on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $23.00.

Zevra Therapeutics Trading Down 6.0 %

NASDAQ ZVRA opened at $7.58 on Tuesday. The company’s 50-day simple moving average is $7.07 and its two-hundred day simple moving average is $5.72. Zevra Therapeutics has a one year low of $3.89 and a one year high of $8.95. The company has a market capitalization of $317.25 million, a price-to-earnings ratio of -5.61 and a beta of 1.94. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The business had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same period last year, the firm earned ($0.15) EPS. Equities analysts forecast that Zevra Therapeutics will post -1.58 EPS for the current fiscal year.

Insider Activity

In related news, Director Thomas Anderson bought 10,000 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was bought at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the purchase, the director now directly owns 20,000 shares of the company’s stock, valued at $136,200. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have purchased a total of 22,000 shares of company stock worth $140,340 over the last 90 days. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD purchased a new stake in Zevra Therapeutics during the 1st quarter valued at about $64,000. The Manufacturers Life Insurance Company boosted its position in Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares during the last quarter. Focus Financial Network Inc. ADV purchased a new stake in Zevra Therapeutics in the fourth quarter valued at approximately $141,000. Virtu Financial LLC acquired a new position in Zevra Therapeutics in the 4th quarter worth approximately $177,000. Finally, Jacobs Levy Equity Management Inc. raised its position in Zevra Therapeutics by 102.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after buying an additional 17,557 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.